When President Barack Obama signed the 21st Century Cures Act into law on December 13, he ensured $4.8 billion in federal funding to advance his own Precision Medicine Initiative, as well as the Cancer Moonshot program led by Vice President Joe Biden, which also prioritizes precision medicine. But even before the law passed, enthusiasm was on the rise for precision cancer drug trials—research aimed at matching patients with drug therapies designed to attack specific genetic mutations in their tumors.
Read Full Article »
